綜上所述，本研究不僅深入分析了LNP技術在mRNA領域的專利狀況，還探討了專利政策對技術創新和公共衛生的複雜影響，為相關利益者提供了寶貴的見解和策略建議，有助於促進技術創新並維護公共利益。;This study delves into the patent landscape of Lipid Nanoparticle (LNP) technology in the mRNA field and analyzes its technological innovation in the biomedical domain. It aims to reveal whether technological innovation follows the linear model of technology and examines in-depth the core technical teams, key patents, and the development of related vaccine patents.Previous research has inadequately focused on the patent landscape and disputes concerning LNP technology and mRNA vaccines. This study fills this gap. Employing diverse methodologies such as literature citation analysis, patent analysis, and case studies of patent litigation, we comprehensively outline the current patent status of LNP technology and discuss the impact of patent thickets on technological innovation, along with the practical effects of patent exemption policies.
Our findings indicate that LNP technology plays a pivotal role in the development of mRNA vaccines, aligning with the linear model of technology innovation. The study also identifies significant contributions of academic institutions such as the University of Pennsylvania and MIT in basic research, while companies like Moderna and BioNTech hold significant positions in patent applications and market competition. Furthermore, phenomena like patent thickets and cases of patent litigation suggest that the exercise of patent rights can significantly impact technological innovation and public health interests.
In summary, this research not only analyzes in depth the patent status of LNP technology in the mRNA field but also explores the complex impact of patent policies on technological innovation and public health. It provides valuable insights and strategic recommendations for stakeholders, aiding in the promotion of technological innovation and the safeguarding of public interests.
